BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Selecta Biosciences, Inc. 

480 Arsenal Street
Building One
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-923-1400 Fax: 617-924-3454


SEARCH JOBS










 Company News
Selecta And Genethon Collaborate To Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform 5/13/2015 10:08:43 AM
Sanofi (SAN.PA) Adds Celiac Disease to the Menu With $300 Million Selecta Bet 5/13/2015 5:59:40 AM
Selecta Biosciences, Inc. To Webcast Presentation At Needham & Company’s 14th Annual Healthcare Conference 4/6/2015 10:27:12 AM
Selecta Biosciences, Inc. And Skolkovo Foundation Collaboration To Develop A Synthetic Vaccine Particle In The Field Of Immuno-Oncology 12/23/2014 10:30:41 AM
Selecta Biosciences, Inc., Juvenile Diabetes Research Foundation And Sanofi (SAN.PA) Extend Collaboration To Develop A Synthetic Vaccine Particle Immunotherapy For Type 1 Diabetes 10/15/2014 9:41:07 AM
Selecta Biosciences, Inc. Announces More Than $20 Million In Equity Funding 10/15/2014 6:29:47 AM
3SBio Inc. (SSRX) Exclusively Licenses Pegsiticase (Uricase PEG-20) To Selecta Biosciences, Inc. To Develop Drug Candidate To Treat Gout 6/18/2014 9:20:48 AM
Selecta Biosciences, Inc. Accelerates Immune Tolerance Therapeutics And Announces New Product Candidate, SEL-212, For Refractory And Tophaceous Gout 6/17/2014 12:56:44 PM
Selecta Biosciences, Inc. Enters Into Exclusive License Agreement With 3SBio Inc. (SSRX) To Develop Drug Candidate To Treat Gout 6/17/2014 11:29:08 AM
Selecta Biosciences, Inc. To Accelerate Program For Novel Dual Action Vaccine For Malaria 6/17/2014 10:11:42 AM
123